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The Organisation for Economic Co-operation
and Development (OECD) began the devel-
opment of new and revised guidelines for the
screening and testing of potential endocrine
disrupters in 1998 (OECD 1998a). One
activity is the validation of the rodent
uterotrophic bioassay, an in vivo screen to
identify suspected estrogen agonists or anta-
gonists of estrogen. A validation management
group (VMG, mammalian) has managed the
uterotrophic validation program and has
reported to the Task Force on Endocrine
Disrupters Testing and Assessment.
Organization of the Validation
Program
OECD Test Guidelines are used in all its
member countries for purposes of the regula-
tory assessment of chemicals, and the valida-
tion program was international in scope. This
international nature introduced numerous
challenges, including different languages, the
logistics of chemical distribution to nine
countries, and the collection and statistical
analysis of the validation data. The validation
program was conducted by a VMG that rec-
ognized and addressed these challenges. The
VMG designed the program to be consistent
with recognized validation principles
(ECVAM 1995; ICCVAM 1997; OECD
1998b). The process from initial discussions
to develop the protocol to the completion of
the reports and the following manuscripts has
taken 4 years.
The ﬁrst challenge was that the protocols
required ﬂexibility, as the animal strains, ani-
mal husbandry supplies, vehicles, and
reagents had to be widely and readily avail-
able among the OECD member countries.
Any rigorous and detailed standardization of
all of these variables would have constrained
the future ability to widely and easily practice
the uterotrophic bioassay in many of the
OECD member countries. To acquire, store,
and distribute the chemicals, a central reposi-
tory was established to deal with interna-
tional shipments, including different customs
regulations and laboratory safety regulations.
The repository was kindly funded by the
chemical industry of Europe and Japan. The
VMG authored and then distributed the
draft protocols for comments to all national
authorities and participating laboratories,
including inquiries for any language ambigu-
ities. To avoid language issues, laboratory
procedures were videotaped, and videotapes
were distributed to the technical staff of all
the participating laboratories. A common
electronic spreadsheet was constructed and
distributed for comment so the data could be
recorded and electronically transmitted to
the independent statistician.
The VMG organized the validation
program in two major phases. Phase 1 was
conducted as a protocol demonstration with
potent references including an estrogen
agonist, 17α-ethinyl estradiol (EE), and
antagonist, ZM 189,154 (Kanno et al. 2001;
OECD 2001). Phase 2 was conducted with
compounds with weak agonists that likely
represented target compounds of regulatory
interest. To assess the predictivity of the
uterotrophic bioassay, the weak agonists were
selected because of the availability of repro-
ductive and developmental studies with a bat-
tery of estrogen-sensitive end points (Chapin
et al. 1999; Tyl et al. 2002). The chemicals
were also selected with a range of potencies
and different metabolic and pharmacokinetic
properties in mind. Kanno et al. (2003a,
2003b) provide additional details on the
chemical selections.
The VMG also oversaw the statistical
analyses, the development of OECD program
reports, the production of the detailed back-
ground review document, and the publica-
tion of the manuscripts. We thank VMG
participants for their dedicated efforts over
the past 4 years and their contribution to the
success of this program.
Detailed Background Review
Document
An essential part of a validation program is
the detailed background review document.
The OECD document has been completed
(OECD 2003) and published in the
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The Organisation for Economic Co-operation and Development has undertaken an international
validation program for the rodent uterotrophic bioassay. This validation program comprised two
major parts. The ﬁrst part was the development of a detailed background review document compil-
ing the existing data on the bioassay’s history, the molecular and physiologic basis for the bioassay’s
mechanistic relevance to detect estrogen agonists and antagonists, a review of important bioassay
protocol parameters, and a review of the data generated by in vitro assays, previous uterotrophic
bioassays, and developmental and reproductive assays to assess and support the overall predictivity of
the uterotrophic bioassay. The second part was an extensive multiyear effort managed by a validation
management group to demonstrate the operating characteristics of four protocols. The effort was
conducted in two phases. The phase 1 results with the reference agonist ethinyl estradiol (EE) and
antagonist ZM 189,154 has been published previously. This Environmental Health Perspectives
mini-monograph is devoted to the phase 2 work using ﬁve weak estrogen agonists, bisphenol A,
genistein, methoxychlor, nonylphenol, and o,p´-DDT, as well as the negative substance dibutyl-
phthalate. These data show that all protocols successfully detected increases in uterine weights when
a sufﬁcient dose level of the weak agonists was administered, whether the substances were known or
provided as coded doses to the laboratory. The data with both the reference EE and all ﬁve weak ago-
nists are reproducible over time and under a variety of different experimental conditions (e.g., animal
strain, diet, housing, bedding, vehicle, animal age). In conclusion, all protocols now have sufﬁcient
data to support their validity. Key words: endocrine disruption, estrogen, rat uterus, uterotrophic,
validation. Environ Health Perspect 111:1527–1529 (2003). doi:10.1289/ehp.6413 available via
http://dx.doi.org/ [Online 8 August 2003]
Rat Uterotrophic Bioassay Mini-Monographpeer-reviewed literature (Owens and Ashby
2002). The background document comprises
several parts. The first part is the history of
the development and use of the uterotrophic
bioassay beginning in the 1930s to identify
potent estrogens and to allow their purifica-
tion and structural elucidation. In subsequent
decades, the bioassay was modiﬁed as part of
the drug discovery process for estrogen ago-
nists and antagonists and has been combined
with preceding receptor binding and reporter
gene transcriptional assays.
The second part provides the essential
background to support the relevance of the
uterotrophic bioassay. Uterine growth is the
result of a cascade of events beginning with
the docking of an agonist ligand with the
estrogen receptor-α and culminating in cell
division and growth of uterine tissues. The
background document details the extensive
work in this area including estrogen receptor
knockout mice and antagonists. This body of
work supports that the uterotrophic bioassay
and the use of uterine growth is directly
mechanistically based and is not empirical or
correlative in nature.
The third part provides a detailed and
critical review of the protocol variations and
parameters. This includes work with rats and
mice, immature females and ovariectomized
females (as both have the requisite low
endogenous circulating estrogen levels), the
dissection and processing of the uterus (where
imbibed fluid is often removed by blotting
before weighting), and the possibility of sup-
porting measurements such as histology to
measure changes in the cell height of the
uterine epithelium.
The fourth part uses several compounds
as examples for a review of estrogen receptor
binding, in vitro reporter gene transcriptional
assays, pharmacokinetic experiments, and a
body of reproductive and developmental data.
This portion of the review presents evidence
that the uterotrophic bioassay results appear
to be generally concordant with estrogen
effects (e.g., acceleration of vaginal opening)
in several reproductive and developmental
assays. Where not concordant, other toxicities
such as body weight losses occur at lower
doses than indicated by the uterotrophic
bioassay.
In conclusion, the detailed background
review indicates that the uterotrophic bioassay
is mechanistically relevant and that existing
data indicate that the uterotrophic bioassay is
predictive in practice.
Phase 2 Validation Studies
The phase 2 validation studies were designed
to generate the data to assess the reliability
and reproducibility characteristics of the
uterotrophic bioassay with weak estrogen
receptor agonists and a negative substance.
Responses consistent with an estrogen mode
of action by the test chemicals were measured
as a statistically signiﬁcant increase in uterine
weight versus vehicle-treated controls. The
weights of uteri containing luminal ﬂuid (wet
weight) and with the luminal fluid removed
(blotted weight) were examined to determine
the procedure that provided the most reliable
data or whether either approach could
be used.
Phase 1 of the validation of the rodent
uterotrophic bioassay involved 19 laboratories
and measured responses of the animals to a
potent reference estrogen, EE. Despite differ-
ences in rat strains, vehicles, and diets used as
well as different levels of experience among
the participating laboratories, there was
acceptable agreement among laboratories with
respect to the doses at which statistically sig-
nificant responses were obtained for a given
protocol (Kanno et al. 2001; OECD 2001).
Phase 2 involved 20 laboratories and seven
test substances. These included the reference
estrogen EE and five weak estrogen agonists
that were three or more orders of magnitude
lower in estrogen receptor binding afﬁnity than
in EE: bisphenol A (BPA), 1,1,1-trichloro-2,2-
bis(o,p´-chlorophenyl)methane or o,p´-DDT
(DDT), genistein (GN), methoxychlor (MX),
and nonylphenol (NP). The weak agonists
were tested in dose–response experiments with
up to five doses per chemical and were
provided blind to the laboratories in coded sin-
gle-dose experiments. The coded single-dose
experiments also included one chemical
(dibutylphthalate; DBP) as a negative chemical
having no estrogenic binding afﬁnity or biolog-
ical activity in well-designed and well-
conducted studies.
All protocols were able to detect each of
the ﬁve weak estrogen agonists, provided suf-
ficient dose levels were administered. In
phase 1, the minimal effective dose (MED;
the lowest dose concentration in a series
achieving statistical significance) for EE in
protocol A by oral gavage was 0.3–1.0
mg/kg/day and in protocols B, C, and D by
sc injection was 0.1–0.3 mg/kg/day. In phase
2, the MEDs of the weak agonists by oral gav-
age ranged from less than 20 mg/kg/day for
MX to 600 mg/kg/day for BPA; the latter
MED was approximately 600,000-fold higher
than that for EE by the same route of expo-
sure. The pooled dose responses for these
chemicals are shown in Figure 1. This demon-
strates the capability of the uterotrophic bio-
assay to detect estrogen agonists over a
substantial concentration range.
The first article in this mini-monograph
relates the results of the dose–response
studies (Kanno et al. 2003b). The magnitude
and shape of the dose–response curve for
each of the ﬁve individual weak agonists was
similar within a protocol. In several protocols,
no differences were observed in the MED,
and in other protocols, the MED fell within
a 3- to 4-fold concentration range despite
differences in rat strains, diets, and other
variables. No protocol or route of administra-
tion was clearly superior in the dose–response
experiments. An additional observation from
these MED data is that a blotted uterine
weight increase of about 30–40% relative to
controls results in statistical signiﬁcance with
a group size of six in a number of cases
(Kanno et al. 2003b).
The second article relates the results of
the coded dose studies (Kanno et al. 2003a).
Here, the single doses selected were intended
to be near the midpoint or in the upper half
of a dose–response curve [ED50–ED80 (effec-
tive dose concentration leading to approxi-
mately 50% of the maximum observed
response in the uterine weight increase–
effective dose concentrations leading to
approximately 80% of the maximum
observed response in the uterine weight
increase)]. For some substances, however, the
selected doses were actually near the MED in
the low region of the dose–response curve. As
this would place the dose in the low region of
the dose–response curve, it would be antici-
pated that some laboratories would not
achieve statistical significance. This, in fact,
was the result (Table 1). The essential point
is the dose dependency of a positive out-
come. A positive chemical will consistently
test positive only if a sufficient dose level is
administered. As the dose is lowered, there
will be a decreasing rate of positive results
among laboratories until no statistically sig-
nificant increase in uterine weight is
achieved, a no-effect level across all laborato-
ries. The other essential point is that there
was reproducibility of the rate of positive
detection at a given dose within the same
protocol across laboratories (Table 1) when
comparing the same administered dose to the
MED calculated from the dose–response
experiments.
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Figure 1. Mean uterine weight increase relative to
vehicle control pooled across laboratories.
Immature female rats were administered test sub-
stance doses by oral gavage for 3 consecutive
days. The substances were EE, DDT, MX, GN , NP,
and BPA. The third article relates the results of
phytoestrogen analyses of the laboratory diets
(Owens et al. 2003). The concern was that
the responsiveness of the bioassay and its abil-
ity to detect weak agonists might be dimin-
ished by phytoestrogens, and all diets were
found to contain phytoestrogens. An exami-
nation of the vehicle control weights and the
responses to the weak agonists in different
laboratories was made relative to an estimated
dietary intake of phytoestrogens. The data
indicated that no effect was evident on the
responsiveness of the ovariectomized female
to weak estrogen agonists. However, the data
were suggestive of an effect for the immature
rat model when GN intakes would exceed
50 mg/kg/day. This level is consistent with
other toxicologic studies showing a lowest
observable effect level in this range as well as
the MED values in the dose–response studies.
A review of rodent food consumption intakes
revealed an approximate ratio for ovari-
ectomized adult rats:immature rats:adult mice
of 1:2:4 for food consumption on a kilogram
of body weight basis. This would then lead to
progressively higher phytoestrogens intakes.
Although any conclusions must be drawn
with caution until further more-controlled
studies are done, experiments with immature
rats or mice should consider limiting the
dietary content of phytoestrogens to about
350 mg phytoestrogens/g diet and 175 mg
phytoestrogens/g diet, respectively.
The fourth article relates the results of
experiments addressing an animal husbandry
variable, the housing of male and female
animals in close proximity and the possible
impact on female uterine weights (Ashby et
al. 2003). In mice, housing adult males in
close proximity to immature females can lead
to premature puberty when the vomeronasal
organs of the females are exposed to male
urine. For the uterotrophic bioassay, this
could mean that the response of these females
would then be reduced. These studies directly
tested this hypothesis in both rats and mice
and found no effect on the uterotrophic
bioassay.
Conclusions
This mini-monograph completes a successful,
4-year international validation program for
the uterotrophic bioassay conducted under
the auspices of the OECD. This success is
due to the cooperation and sustained efforts
of numerous scientists, participating laborato-
ries, organizations, statisticians, and others.
Thanks and congratulations are due to the
many contributors.
The OECD validation studies demon-
strate that the uterotrophic bioassay protocols
are robust and reliable for identifying estrogen
agonists and antagonists and are transferable
across laboratories. Both the immature and
ovariectomized rat protocols were highly
reproducible among laboratories and were
able to identify weak estrogen agonists, pro-
vided sufﬁcient dose levels were administered.
In conclusion, the rat uterotrophic bioassay,
using either immature or ovariectomized ani-
mals, can be used as an effective screen for
weak and potent estrogenic agonists.
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Table 1. Immature and ovariectomized female rat comparing the MED and statistically signiﬁcant results
reported as positive identiﬁcation/total number of trials.
Administered Immature female Ovariectomized female
Test dose by sc MEDa Coded Dose MEDa Coded Dose
substance (mg/kg/day) (mg/kg/day) dose response (mg/kg/day) dose response
BPA 300 300 14/15 7/9 100 7/7 5/5
o,p´-DDT 100 200 6/16 1/4 100 4/7 1/3
GN 35 15 14/14 4/4 15 6/6 3/3
MX 500 100 15/15 4/4 100 6/6 3/3
NP 80 80 12/16 6/9 80 5/6 2/5
aMED given for pooled studies for a given protocol. Derived from dose–response experiments of Kanno et al. (2003b).